Serum heart-fatty acid binding protein levels in patients with Lewy body disease.
OBJECTIVE
In order to examine a possible role of serum heart-fatty acid binding protein (H-FABP) in patients with Lewy body disease, we measured serum levels of H-FABP in patients with dementia with Lewy bodies (DLB), Parkinson's disease (PD), and Alzheimer's disease (AD).


METHODS
Serum levels of H-FABP were measured using a solid-phase enzyme-linked immunoassay. Iodine-123 metaiodobenzylguanidine ((123)I-MIBG) cardiac scintigraphy was performed on each patient and the heart to mediastinum (H/M) ratio was calculated. Receiver operating characteristic (ROC) analysis was used to calculate the optimal cutoff values of the H-FABP between DLB and AD patients. Independent predictive variables for serum H-FABP levels were analyzed using multivariate regression analysis.


RESULTS
Serum levels of H-FABP were significantly higher in DLB patients and PD patients than in AD patients. H/M ratios of the DLB and PD patients were significantly lower than those of AD patients. The diagnostic value of the serum H-FABP levels between AD and DLB patients was inferior to that of the delayed H/M ratio of (123)I-MIBG cardiac scintigraphy. Multivariate regression analysis revealed that the delayed H/M ratio predicted serum H-FABP levels in the PD patients.


CONCLUSIONS
Examination of serum H-FABP levels did not allow discrimination between DLB and AD patients. Cardiac sympathetic nerve dysfunction may be associated with elevation of serum H-FABP in Lewy body disease patients.
Wada-Isoe
Kenji
K
Department of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago, 683-8504, Japan. kewada@grape.med.tottori-u.ac.jp
Imamura
Keiko
K
Kitamaya
Michio
M
Kowa
Hisanori
H
Nakashima
Kenji
K
D019797:3-Iodobenzylguanidine; D000368:Aged; D000544:Alzheimer Disease / Q000097:blood / Q000000981:diagnostic imaging; D019540:Area Under Curve; D015415:Biomarkers; D003937:Diagnosis, Differential; D018491:Dopamine Agonists / Q000627:therapeutic use; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging; D006801:Humans; D020961:Lewy Body Disease / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy; D008297:Male; D008482:Mediastinum / Q000000981:diagnostic imaging; D010300:Parkinson Disease / Q000097:blood / Q000000981:diagnostic imaging; D012372:ROC Curve; D019275:Radiopharmaceuticals; D015899:Tomography, Emission-Computed, Single-Photon
D015415:Biomarkers; D018491:Dopamine Agonists; C493408:FABP3 protein, human; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine